Novo Nordisk to apply Zosano's delivery system to Type II diabetes candidate; deal terminated
Executive Summary
Zosano Pharma Inc. (transdermal drug delivery) granted Novo Nordisk AS exclusive worldwide rights to use its microneedle patch system in the development and commercialization of glucagon-like peptide-1 (GLP-1) analogues.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Transdermal
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice